FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245200411> ?p ?o ?g. }

• W4245200411 endingPage "2825" @default.
• W4245200411 startingPage "2825" @default.
• W4245200411 abstract "Abstract Abstract 2825 Mantle cell lymphoma (MCL) constitutes one of the lymphomas with poorest prognosis at relapse and there are no effective salvage. The activity shown by the combination Gemcitabine and Oxaliplatin in several types of limfoma, along with its “in vitro” synergistic effect, made this regimen an attractive regimen for salvaging patients with MCL. Against this background, we performed an off-label pilot study in order to assess efficacy and toxicity of the combination R-GemOx in relapsed or refractory patients with MCL. For this, 27 patients (70% male, median age 70 years) diagnosed with MCL between November 2004 and January 2010 were included in this study. Inclusion criteria were adequate performance status, confirmed diagnosis of MCL and relapse or refractoriness to the previous treatment. The regimen consisted of Rituximab 375 mg/m2 on day 1, Gemcitabine 1000 mg/m2 and Oxaliplatin 100 mg/m2 on day 2, every 14 days, up to 8 cycles. Dose and interval were adjusted according to hematological and extrahematological toxicities. Median number of previous regimens was 1 (range 1 to 3), being EPOCH-R (n=14), R-CHOP (n=6), and RFC (n=3) the most frequently used induction therapies. Twelve patients relapsed after prior CR, 10 progressed after achieving a PR, whereas 5 were refractory to therapy. At inclusion, 85% of patients were in advanced (III/IV) clinical stage, 40% had bone marrow infiltration, 28% gastrointestinal involvement, and 17% cavum infiltration. Median number of cycles administered was 8 (range, 3 to 8). Doses were reduced in 9 cycles and delayed in 15 cycles. Neutropenia grade 3–4 was observed in 9 cycles and thrombocytopenia grade 3–4 in 6. Hepatotoxicity grade 1–2 in 5 pts and grade 3 in 1, sensitive neurotoxicity grade 1–2 in 12 pts, and renal impairment grade 2 in 1 patient. After completion of the treatment, 21 pts (77%) were considered in CR/uCR, 1 (4%) achieved a PR, 1 a SD, whereas 4 PD. Six patients subsequently received a stem-cell transplantation (4 allogeneic, 2 autologous). Thirteen pts are still alive and out of progression. Ten pts have died (8 due to progression and 2 due to acute GVHD). With a median follow-up of 23 months (range: 3–57), PFS and OS at 2 years are 41% and 58%, respectively. The R-GemOx combination showed a significant activity in relapsed or refractory pts with MCL with a very acceptable toxicity profile. These results prompted us to conduct a multicenter phase II clinical trial that is now ongoing. Disclosures: López: Roche Farma: Research Funding, Travel Support. Bosch:Roche Farma: Research Funding." @default.
• W4245200411 created "2022-05-12" @default.
• W4245200411 creator A5007117385 @default.
• W4245200411 creator A5021328479 @default.
• W4245200411 creator A5024884072 @default.
• W4245200411 creator A5032390074 @default.
• W4245200411 creator A5054008156 @default.
• W4245200411 creator A5078340362 @default.
• W4245200411 date "2010-11-19" @default.
• W4245200411 modified "2023-09-30" @default.
• W4245200411 title "Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma." @default.
• W4245200411 doi "https://doi.org/10.1182/blood.v116.21.2825.2825" @default.
• W4245200411 hasPublicationYear "2010" @default.
• W4245200411 type Work @default.
• W4245200411 citedByCount "2" @default.
• W4245200411 countsByYear W42452004112013 @default.
• W4245200411 countsByYear W42452004112015 @default.
• W4245200411 crossrefType "journal-article" @default.
• W4245200411 hasAuthorship W4245200411A5007117385 @default.
• W4245200411 hasAuthorship W4245200411A5021328479 @default.
• W4245200411 hasAuthorship W4245200411A5024884072 @default.
• W4245200411 hasAuthorship W4245200411A5032390074 @default.
• W4245200411 hasAuthorship W4245200411A5054008156 @default.
• W4245200411 hasAuthorship W4245200411A5078340362 @default.
• W4245200411 hasConcept C121332964 @default.
• W4245200411 hasConcept C121608353 @default.
• W4245200411 hasConcept C126322002 @default.
• W4245200411 hasConcept C141071460 @default.
• W4245200411 hasConcept C142424586 @default.
• W4245200411 hasConcept C143998085 @default.
• W4245200411 hasConcept C2776694085 @default.
• W4245200411 hasConcept C2777525834 @default.
• W4245200411 hasConcept C2778041864 @default.
• W4245200411 hasConcept C2778336483 @default.
• W4245200411 hasConcept C2779338263 @default.
• W4245200411 hasConcept C2780258809 @default.
• W4245200411 hasConcept C2780653079 @default.
• W4245200411 hasConcept C2780775027 @default.
• W4245200411 hasConcept C2780962732 @default.
• W4245200411 hasConcept C2781413609 @default.
• W4245200411 hasConcept C526805850 @default.
• W4245200411 hasConcept C71924100 @default.
• W4245200411 hasConcept C87355193 @default.
• W4245200411 hasConcept C90924648 @default.
• W4245200411 hasConceptScore W4245200411C121332964 @default.
• W4245200411 hasConceptScore W4245200411C121608353 @default.
• W4245200411 hasConceptScore W4245200411C126322002 @default.
• W4245200411 hasConceptScore W4245200411C141071460 @default.
• W4245200411 hasConceptScore W4245200411C142424586 @default.
• W4245200411 hasConceptScore W4245200411C143998085 @default.
• W4245200411 hasConceptScore W4245200411C2776694085 @default.
• W4245200411 hasConceptScore W4245200411C2777525834 @default.
• W4245200411 hasConceptScore W4245200411C2778041864 @default.
• W4245200411 hasConceptScore W4245200411C2778336483 @default.
• W4245200411 hasConceptScore W4245200411C2779338263 @default.
• W4245200411 hasConceptScore W4245200411C2780258809 @default.
• W4245200411 hasConceptScore W4245200411C2780653079 @default.
• W4245200411 hasConceptScore W4245200411C2780775027 @default.
• W4245200411 hasConceptScore W4245200411C2780962732 @default.
• W4245200411 hasConceptScore W4245200411C2781413609 @default.
• W4245200411 hasConceptScore W4245200411C526805850 @default.
• W4245200411 hasConceptScore W4245200411C71924100 @default.
• W4245200411 hasConceptScore W4245200411C87355193 @default.
• W4245200411 hasConceptScore W4245200411C90924648 @default.
• W4245200411 hasIssue "21" @default.
• W4245200411 hasLocation W42452004111 @default.
• W4245200411 hasOpenAccess W4245200411 @default.
• W4245200411 hasPrimaryLocation W42452004111 @default.
• W4245200411 hasRelatedWork W17733091 @default.
• W4245200411 hasRelatedWork W19219843 @default.
• W4245200411 hasRelatedWork W21149459 @default.
• W4245200411 hasRelatedWork W21933366 @default.
• W4245200411 hasRelatedWork W2293350 @default.
• W4245200411 hasRelatedWork W23389499 @default.
• W4245200411 hasRelatedWork W4351535 @default.
• W4245200411 hasRelatedWork W4429043 @default.
• W4245200411 hasRelatedWork W5279832 @default.
• W4245200411 hasRelatedWork W6531846 @default.
• W4245200411 hasVolume "116" @default.
• W4245200411 isParatext "false" @default.
• W4245200411 isRetracted "false" @default.
• W4245200411 workType "article" @default.